Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions

British Journal of Cancer

Volumn 109, Issue 4, 2013, Pages 1072-1078

  Moon, D H ^a,b   Lee, J M ^a   Noonan, A M ^a   Annunziata, C M ^a   Minasian, L ^a   Houston, N ^a   Hays, J L ^a   Kohn, E C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; GROWTH FACTOR; METHYLPREDNISOLONE; OLAPARIB; OXALIPLATIN; PACLITAXEL; RANITIDINE;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; BRCA2 GENE; CHEST TIGHTNESS; CLINICAL TRIAL (TOPIC); DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FLUSHING; GENE MUTATION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NAUSEA AND VOMITING; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RISK FACTOR; SIDE EFFECT; TACHYCARDIA; THROAT TIGHTNESS; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; DRUG HYPERSENSITIVITY; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; ODDS RATIO; OVARIAN NEOPLASMS; PHTHALAZINES; PIPERAZINES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84883165337     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.389     Document Type: Article

References (30)

1. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30: 2654-2663.
2. Ben David Y, Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck BD, Beller U, Ben-Baruch G, Fishman A, Levavi H, Lubin F, Menczer J, Piura B, Struewing JP, Modan B (2002) Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 20: 463-466.
3. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365: 2473-2483.
4. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S (2008) Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 26: 20-25.
5. Confino-Cohen R, Fishman A, Altaras M, Goldberg A (2005) Successful carboplatin desensitization in patients with proven carboplatin allergy. Cancer 104: 640-643.
6. Datta R, Naura AS, Zerfaoui M, Errami Y, Oumouna M, Kim H, Ju J, Ronchi VP, Haas AL, Boulares AH (2011) PARP-1 deficiency blocks IL-5 expression through calpain-dependent degradation of STAT-6 in a murine asthma model. Allergy 66: 853-861.
7. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921.
8. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134.
9. Gadducci A, Tana R, Teti G, Zanca G, Fanucchi A, Genazzani AR (2008) Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer 18: 615-620.
10. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12: 852-861.
11. Gomez R, Harter P, Luck HJ, Traut A, Kommoss S, Kandel M, du Bois A (2009) Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study. Int J Gynecol Cancer 19: 1284-1287.
12. Gutierrez M, Pautier P, Lhomme C (2002) Replacement of carboplatin by oxaliplatin may be one solution for patients treated for ovarian carcinoma who are hypersensitive to carboplatin. J Clin Oncol 20: 353.
13. Husain A, He G, Venkatraman ES, Spriggs DR (1998) BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 58: 1120-1123.
14. Joly F, Ray-Coquard I, Fabbro M, Donoghoe M, Boman K, Sugimoto A, Vaughan M, Reinthaller A, Vergote I, Ferrandina G, Dell'Anna T, Huober J, Pujade-Lauraine E (2011) Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial. Gynecol Oncol 122: 226-232.
15. Jones R, Ryan M, Friedlander M (2003) Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation. Gynecol Oncol 89: 112-115.
16. Koshiba H, Hosokawa K, Kubo A, Miyagi Y, Oda T, Watanabe A, Honjo H (2009) Incidence of Carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies. Int J Gynecol Cancer 19: 460-465.
17. Lee CW, Matulonis UA, Castells MC (2004) Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol 95: 370-376.
18. Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW (2010) Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs 2010: 1-10.
19. Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, Belinson J (1999) Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17: 1141.
20. Markman M, Zanotti K, Kulp B, Peterson G (2003) Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity. Gynecol Oncol 89: 514-516.
21. Morgan JS, Adams M, Mason MD (1994) Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma. Eur J Cancer 30A: 1205-1206.
22. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21: 3194-3200.
23. Polyzos A, Tsavaris N, Kosmas C, Arnaouti T, Kalahanis N, Tsigris C, Giannopoulos A, Karatzas G, Giannikos L, Sfikakis PP (2001) Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 61: 129-133.
24. Rose PG, Fusco N, Smrekar M, Mossbruger K, Rodriguez M (2003) Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. Gynecol Oncol 89: 429-433.
25. Schwartz JR, Bandera C, Bradley A, Brard L, Legare R, Granai CO, Dizon DS (2007) Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital. Gynecol Oncol 105: 81-83.
26. Sugimoto H, Iwamoto T, Murashima Y, Tabata T, Sagawa N, Okuda M (2011) Risk factors contributing to the development of carboplatin-related delayed hypersensitivity reactions in Japanese patients with gynecologic cancers. Cancer Chemother Pharmacol 67: 415-419.
27. TCGARNetwork. (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
28. Tonkin KS, Rubin P, Levin L (1993) Carboplatin hypersensitivity: case reports and review of the literature. Eur J Cancer 29A: 1356-1357.
29. USPSTF (2005) Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 143: 355-361.
30. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363: 943-953.